Observational Study of Pergolide Mesylate and Cardiac Valvulopathy

计划入组 200 人 · 首次发布于 2006 年 4 月 6 日

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events

计划入组 86,939 人 · 首次发布于 2010 年 1 月 21 日

Valvular Microbiota and Valvulopathy

计划入组 100 人 · 首次发布于 2024 年 5 月 9 日

Pergolide(Permax)

C₁₉H₂₆N₂S

cardiac selective mineralocorticoid receptor inhibitors (oral, cardiac failure/cardiac fibrosis)

Cardiac Fibrosis(Hepion)

Cardiac Implants LLC

United States

CARDIAC DIMENSIONS PTY. LTD.

Australia

TEXAS CARDIAC ARRHYTHMIA RESEARCH FOUNDATION

United States

Machine Learning Model Achieves 96% Accuracy in Predicting Breast Cancer Treatment-Related Cardiac Events

atai Life Sciences Secures $11.4 Million NIH Grant for Non-Hallucinogenic Opioid Use Disorder Treatment

APA 2026: Real-World GAD Treatment Gaps and Preclinical Safety Data for 5-HT2A Agonist DT120